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ABSTRACT 
Background: Total splenectomy (TS) and partial splenectomy (PS) are used for children 
with congenital hemolytic anemia (CHA), although the long-term outcomes of these 
procedures are poorly defined. This report describes long-term outcomes of children with 
CHA requiring TS or PS. 
Procedure: We collected data from children ages 2-17 with hereditary spherocytosis (HS) or 
sickle cell disease (SCD) requiring TS or PS from 1996 to 2016 from 14 sites in the 
Splenectomy in Congenital Hemolytic Anemia (SICHA) consortium using a prospective, 
observational patient registry. We summarized hematologic outcomes, clinical outcomes, and 
adverse events to 5 years after surgery. Hematologic outcomes were compared using mixed 
effects modeling. 
Results: Over the study period, 110 children with HS and 97 children with SCD underwent 
TS or PS. From preoperatively compared to postoperatively, children with HS increased their 
mean hemoglobin level by 3.4 g/dL, decreased their mean reticulocyte percentage by 6.7%, 
and decreased their mean bilirubin by 2.4mg/dL. Hematologic improvements and improved 
clinical outcomes were sustained over 5 years of follow-up. For children with SCD, there was 
no change in hemoglobin after PS or TS following surgery, although all clinical outcomes 
were improved. Over 5 years, there was one child with HS and 5 children with SCD who 
developed post-splenectomy sepsis. 
Conclusions: For children with HS, there are excellent long-term hematologic and clinical 
outcomes following either PS or TS. Although hemoglobin levels do not change after TS or 
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Introduction 
 For severely affected children with congenital hemolytic anemia (CHA) such as 
hereditary spherocytosis (HS) or sickle cell disease (SCD), surgical treatment with total 
splenectomy (TS) is often required.
1,2
 There is continued interest in partial splenectomy (PS) 
due to risks of overwhelming post-splenectomy sepsis, venous thromboembolism, and 
pulmonary hypertension from TS.
3–7
 However, the long-term outcomes of TS and PS remain 




For many clinical practices, there is great value using data from clinical and 
administrative datasets to predict expected health outcomes.
5,8
 However, the use of common 
datasets for the study of less frequent conditions is difficult, as these data sets often do not 
record outcomes considered most important by clinicians and families. In particular, research 
on spleen surgery in CHA is challenged by the heterogeneity of diseases, small number of 
subjects, variations in surgical technique, and use of non-standardized data.
8,13
 In these 
settings, a patient registry is a powerful tool to collect high-quality, standardized data.
11
 
 To improve the care of children with CHA, we have operated the SICHA 
(Splenectomy in Congenital Hemolytic Anemia) consortium, a research consortium 
composed of pediatric surgeons and hematologists across North America. Our group has 
operated a web-based, prospective, patient registry using standardized data to better 
understand the outcomes of children with CHA undergoing TS or PS. We previously have 
shown excellent clinical outcomes as well as hematologic results following TS or PS over 
short-term (one year) follow-up.
14
 The objective of this current report is to summarize the 
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Splenectomy in Children with Congenital Hemolytic Anemia (SICHA) Consortium 
The SICHA consortium was formed to improve the care of children with CHA, with 
participation from 16 sites across North America. Our consortium has operated a combined 
retrospective and prospective, observational, web-based patient registry for children with 
CHA requiring splenectomy using the Research Electronic Data Capture (REDCap) platform. 
The design, data variables, outcome definitions, and operations of this patient registry have 
been described previously.
14,15





Children were offered enrollment in the SICHA registry if they were age 2-17 years 
and underwent either a TS or PS for congenital hemolytic anemia at any SICHA site between 
January 1, 1996 and December 31, 2016. All clinical management, including the decision to 
perform a TS or PS, was conducted locally by the surgeon, hematologist, and family. In 
addition to children with HS or SCD, patients with other type of CHA such as thalassemia or 
pyruvate kinase deficiency were included in the registry, but were excluded from this analysis 
due to low patient numbers. Patients undergoing splenectomy for trauma or reasons other 
than CHA management were not included in this registry. 
From January 1, 1996 to December 31, 2008, we collected data retrospectively for 36 
patients, and from January 1, 2009 to December 31, 2016 we collected data prospectively for 
171 (83%) patients. This study was approved by the Institutional Review Board (IRB) at each 
site in the SICHA consortium, with written informed consent obtained from the parent or 
guardian of all participants prior to participation. Each clinical site retained all identifying 
information, with only deidentified data collected centrally as previously described.
17
 We 
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Data Abstraction 
We collected 68 variables, including patient demographics, diagnosis, hematologic 
outcomes, clinical outcomes, imaging, surgical details, and adverse events (AEs) (see 
previous publication for all variable definitions).
14
 Hematologic outcomes, clinical outcomes, 
and adverse events were collected at baseline, 1 month, 6 months, and then annually at 1, 2, 
3, 4, and 5 years after surgery. 
The primary hematologic outcomes were hemoglobin (g/dL), total bilirubin (mg/dL), 
and reticulocyte level (percentage). The primary clinical outcomes included events of splenic 
sequestration, hypersplenism, aplastic crises, splenomegaly, gallstones, and completion 
splenectomy. Short-term (within 30 days postoperatively) AEs included infection, 
reoperation for total splenectomy after previous partial splenectomy, acute chest syndrome 
(ACS, for SCD patients only), and death. Long-term (from 30 days to 5 years 
postoperatively) AEs included infection, ACS (for SCD patients only), thrombotic events, 
reoperation, and death. Infections captured included sepsis, bacteremia, meningitis, or other 
infection requiring ED admission or hospitalization. 
We defined clinical outcomes and adverse events as following: transfusion 
dependence as participation in regular transfusion program over at least a 3 month interval; 
hypersplenism as chronic splenomegaly associated with thrombocytopenia (platelet counts < 
150,000 ×10
9
/L with or without associated neutropenia or abdominal pain); splenic 
sequestration as an acute increase in spleen size and firmness, reduction of hemoglobin ≥ 
2g/dL which may include drop in platelet or white counts.
18,19
 As we were interested in the 
longitudinal risk of AEs in all children following surgery, we summarized the cumulative 
incidence of any AE during the entire follow-up period for each child as a binary variable 
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therefore excluded from analysis. In addition to data management and quality assurance 





We summarized hematologic outcomes, clinical outcomes, and AEs based on 
diagnosis (HS versus SCD) as well as by type of procedure (PS versus TS). We expressed 
categorical variables as frequency and percentage, and continuous variables by mean and 
interquartile range (IQR). We compared preoperative and postoperative clinical outcomes 
using McNemar’s test for children with available matched data. All clinical events 
(infections, thrombosis, acute chest syndrome) were summarized as risk of events. 
To analyze hematologic outcomes over time, we summarized values with available 
data at each follow-up period. To account for loss to follow-up, we applied a mixed-effects 
model stratified by disease type, operation (total vs. partial), pre- and post-surgery, and time 
point after surgery. Trends in hematologic values over time were used to assess durability of 
changes after surgery. An interaction term between surgery and operation type (total vs. 
partial) was used to evaluate the association of partial splenectomy on changes in 
hematologic values. An interaction term between operation type and time from surgery was 
used to evaluate the durability of hematologic changes over the follow-up period. The study 
was not powered to detected differences in long-term outcomes by type of splenectomy (TS 
vs. PS) or by surgical approach (laparoscopy vs. laparotomy). We summarized unadjusted 
hematologic data graphically as mean ± standard error (SE). All analyses were performed 
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Patient and Operative Characteristics 
 A total of 236 children were enrolled across 16 sites. Twenty-nine subjects were 
excluded from analysis, including 18 children with thalassemia or other CHA, 10 subjects 
with incomplete data, and 1 subject who withdrew from the study. The final analysis cohort 
was comprised of 207 children enrolled from 14 sites (mean 14.7 subjects/site, median 11 
subjects/site). Children had a diagnosis of HS (n=110) or SCD (n=97), with subtypes of SCD 
including hemoglobin (Hgb) SS, Hgb SC, and combined Hgb S/β-thalassemia (Table 1). 
There was a greater number of males than females, with an expected racial and ethnic 
distribution by disease type. Patients were followed to 5 years after surgery, although there 
was relatively large attrition due to loss to follow-up, with follow-up of 133 subjects (64%) at 
6 months, 103 (50%) at 1 year, 124 (60%) at 2 years, 105 (51%) at 3 years, 66 (32%) at 4 
years, and 44 (21%) at 5 years. Patients were lost to follow-up because they either did not 
show up to their clinic appointment within the specified time range, or they moved away and 
established care elsewhere. 
Of the 110 children with HS, 59 received a TS and 51 received a PS. For the 97 
children with SCD, 73 received TS and 24 received a PS. Indications for surgery included 
splenic sequestration (in SCD) or hypersplenism (in HS) (51.7%), splenomegaly (15.5%), 
and transfusion dependence (22.2%). Almost all (91.8%) children received pre-operative 
vaccines, and 98.5% of children received early post-operative (within 30 days of surgery) 
antibiotic prophylaxis, although we did not collect the long-term antibiotic usage rate. Most 
children (91%) undergoing a TS had an initial laparoscopic approach compared to 55% of 
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Hereditary spherocytosis. Children with HS undergoing TS or PS showed 
improvement in all hematologic outcomes over the follow-up period (Fig 1). By unadjusted 
analysis, children who underwent TS increased their mean hemoglobin levels 
postoperatively, with levels sustained to 5 years after surgery (baseline 10.3 ± 0.2 g/dL, 5 
years 13.5 ± 1.9 g/dL; mean ± SE) (Fig 1A). Hemoglobin levels also increased following PS 
and were sustained to 5 years after surgery (baseline 10.1 ± 0.2 g/dL, 5 years 11.9 ± 0.8 g/dL; 
mean ± SE) (Fig 1A). 
Other hematologic outcomes improved after TS or PS in children with HS and were 
sustained to 5 years after surgery. Mean reticulocyte percentages decreased in TS and PS 
cohorts, although the long-term reticulocyte percentages were lower in TS (baseline 
9.3 ± 0.7%, 5 years 2.9 ± 0.8%; mean ± SE) compared to PS (baseline 11.3 ± 0.9%, 5 years 
4.8 ± 1.0 %; mean ± SE) (Fig 1B). Mean bilirubin values decreased following either TS or PS, 
and remained less than 2 mg/dL over 5 years of follow-up (Fig 1C). 
By adjusted analysis, HS children increased their mean hemoglobin level by 3.4 g/dL 
after surgery (95% CI: 3.1-3.7) at 5 years of follow-up. Similarly, mean reticulocyte 
percentage decreased by 6.7% (5.6-7.7%, p<0.001) after surgery. Mean bilirubin levels 
decreased by 2.4 mg/dL (2.0-2.8) after surgery. 
For children with HS, TS had more substantial hematologic improvements than PS. 
The increase in mean hemoglobin at 5 years after surgery was 0.6 g/dL greater following TS 
compared to PS (0.2-1.0 g/dL). The decrease in mean reticulocyte percentage was similar in 
PS compared to TS. Mean bilirubin levels decreased by 0.7 mg/dL less in PS than TS (0.3-
1.2). 
Sickle cell disease. For children with SCD, there was no change in mean hemoglobin 
levels at 5 years after either PS or TS (Fig 2A). Mean reticulocyte percentages decreased 
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with PS and TS (Fig 2C). Mixed model adjusted analysis confirmed that mean hemoglobin 
levels in both cohorts were unchanged after surgery. Reticulocytes decreased 2.0% (0.8-
3.2%) and bilirubin decreased 0.9 mg/dL (0.5-1.3) after PS or TS. 
Clinical Outcomes 
Almost all children with HS or SCD had improvement of clinical outcomes after TS 
or PS (Table 3). For children with HS, there was a decrease in transfusion requirement and 
improvement in all clinical outcomes. Most clinical outcomes in children with SCD were also 
favorable, although some children continued to receive blood transfusions over the follow-up 
period. Both PS and TS were associated with improved splenomegaly, splenic sequestration 
(in SCD), and hypersplenism (in HS). 
Adverse Events 
Short-Term AEs. Overall, the incidence of short-term (<30 days postoperatively) AEs 
was 5.5% among children with HS and 18.6% among children with SCD (Table 4). There 
were no deaths recorded. The most frequently reported short-term AE was infection, with a 
4.5% infection risk in HS and an 8.2% risk in SCD. In children with SCD, there was a 10.3% 
risk of ACS. 
Long-Term AEs. The most common long-term AE (30 days to 5 years 
postoperatively) was infection, predominately upper and lower respiratory tract infections. 
There were no deaths recorded. HS patients undergoing TS or PS had a 13.6% cumulative 
risk of infection, including one patient with sepsis and one with meningitis over 5 years of 
follow-up (Table 4). There were 3 HS patients (5.9%) who required a reoperation for 
completion splenectomy following PS. In children with SCD, there was a cumulative 
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of thrombotic events and a 26.8% risk of ACS. The long-term risk of ACS among children 
with SCD requiring TS was 31.5% and 12.5% in children with PS. 
Discussion 
Although different types of splenectomy are used for severely affected children with 
CHA, the long-term risks and benefits of total and partial splenectomy remain poorly 
understood by families and clinicians. Most existing studies are limited by use of single 
institution reports, absence of standardized data, or limited follow-up.
11,12
 To address this 
research gap, our consortium developed a multisite, web-based prospective patient registry 
based on use of standardized data definitions for children with CHA requiring surgery. We 
have previously demonstrated excellent hematologic and clinical outcomes in children with 
HS after total and partial splenectomy over one year of follow-up, with clinical outcomes 
improved in children with sickle cell disease.
14,15
 In our current study, we found that these 
favorable outcomes are sustained to five years after surgery. Although our study was not 
designed to directly compare surgical procedures, we found that most children with HS or 
SCD undergoing either TS or PS have quite favorable clinical outcomes. 
The patterns of hematologic outcomes differ between HS and SCD following 
splenectomy. For children with HS, both TS and PS result in sustained improvement of 
hematologic laboratory parameters, control of clinical symptoms, and a low risk of adverse 
events to 5 years after surgery. In contrast, for children with SCD, reticulocyte and bilirubin 
did improve after surgery, although hemoglobin levels did not change following TS or PS. 
However, we found favorable clinical outcomes following surgery in children with SCD, 
particularly markedly decreased rates of sequestration crises. Elimination of splenic 
sequestration provides a substantial benefit to children with SCD, as sequestration crises are a 
significant cause of morbidity and mortality.
20,21
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literature that splenectomy does not result in change in hemoglobin levels in children with 
SCD.
8,22
 Many children with SCD continued to receive transfusions after splenectomy, 
although this may reflect the clinical practice in severely affected children with SCD to 
continue transfusion therapy throughout childhood to prevent sickling events and other 
morbidity. 
Our report has several strengths, including its generalizability, multi-institutional 
design, web-based data entry, and use of standardized data definitions. This report of long-
term outcomes of splenectomy should be of great value for clinicians and families to 
understand expected outcomes of different types of splenectomy. As well, our data provides 
robust baseline information to facilitate a clinical trial of TS and PS in children with CHA. 
As the outcomes following either TS or PS are quite favorable, we suggest that any clinical 
trial should focus on factors which impact the decisions related to surgery, such as patient- 
(or family-) preferences, quality of life assessment, and cost-effectiveness analysis. 
Our analysis has several limitations, many of which are inherent to use of an 
observational patient registry. First, our study is not designed to compare the efficacy of 
different surgical procedures or surgical versus medical therapies. Comparison of treatments 
would require a randomized clinical trial, although the many types of CHA, small population, 
and rare adverse events limit the feasibility of such a clinical trial. Secondly, our results are 
limited by the relatively large number of patients lost to follow-up and prone to attrition bias. 
We recognize that patient attrition and missing data is a common challenge for patient 
registries, and we appreciate the diligent data collection by study sites. As well, mixed 
modeling allows for adjustment for missing data. Third, we did not collect several outcomes 
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hospitalization, quality of life measures, and compliance with antibiotic prophylaxis. Fourth, 
we did not examine how disease severity or genotype affects surgical outcomes. 
In conclusion, we found favorable long-term hematologic outcomes, clinical 
outcomes, and rates of AEs in children with HS or SCD undergoing total or partial 
splenectomy. Our results add to existing literature in this area, and should provide 
reassurance to families and providers that TS or PS results in quite favorable outcomes. 
However, clinicians and families considering splenectomy should evaluate all expected risks 
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FIGURE 1 (A-C) Unadjusted hematologic outcomes after partial or total splenectomy in 
children with hereditary spherocytosis. Data represent hemoglobin (A), reticulocyte 
percentage (B), and serum bilirubin (C) at baseline, 4 weeks, 24 weeks, 1 year, 2 years, 3 
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FIGURE 2 (A-C) Unadjusted hematologic outcomes after partial or total splenectomy in 
children with sickle cell disease. Data represent hemoglobin (A), reticulocyte percentage (B), 
and serum bilirubin (C) at baseline, 4 weeks, 24 weeks, 1 year, 2 years, 3 years, 4 years, and 
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TABLE 1 Characteristics of Children with Hereditary Spherocytosis or Sickle Cell Disease Undergoing 
Total Splenectomy (TS) or Partial Splenectomy (PS).  
Patient Characteristics Overall Hereditary Spherocytosis 
(n=110) 
Sickle Cell Disease 
(n=97) 
  TS PS TS PS 
N 207 59 51 73 24 
Demographics  
Sex  
     Male 110  30  26  39  15  
     Female 96  29  25  33  9  
Race   
     White 95  50  41  3  1  
     Black 96  5  3  66  22  
     American Indian/Alaska         
Native 
2 1 1 0 0 
     Asian 1 0 0 0 1 
     More than one race 1 0 0 1 0 
     Not reported 12 3 6 3 0 
Ethnicity  
     Hispanic 10  4  1  2  3  
     Not Hispanic 197 55 50 71 21 
Indication for surgery  
   Splenic sequestration 82 NA NA 61 21 
   Hypersplenism  25 16 9 NA NA 
   Transfusion dependence 46 5 13  24 4 
   Splenomegaly 32 14 16 2 0 
 
Demographic and indication for surgery characteristics illustrated by disease and operative approach. 
In reference to indication for surgery, numbers represent number of patients at baseline. NA - Not 
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TABLE 2 Operative Characteristics of Children with Hereditary Spherocytosis or Sickle Cell Disease 
Undergoing Total Splenectomy (TS) or Partial Splenectomy (PS).  
Operative Characteristics Overall Hereditary Spherocytosis 
(n=110) 
Sickle Cell Disease 
(n=97) 
  TS PS TS PS 
N 207 59 51 73 24 
Initial approach  
    Open 45 5 17 6 17 
    Laparoscopic 161 54 34 66 7 
Laparoscopic converted to open 11 1 5 3 2 
Additional procedure 60 20 15 21 4 
Length of stay (days) 3 (2, 4) 2 (0, 6) 4 (1.5, 5.5) 3 (0,7) 3 (0.4,7.4) 
Postoperative blood transfusion 10 0 3 4 3 
 
Data expressed as number of subjects in each cohort. Continuous data (length of stay) represented 
by median (with interquartile range). Data are based on standard data definitions.
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TABLE 3 Clinical Symptoms at Baseline and After Total Splenectomy (TS) or Partial Splenectomy 







Symptoms summarized as number of children in each cohort at baseline and up to 5 year post-
operatively. Any symptom reported during follow-up period was counted once, with multiple episodes 
of the same symptoms counted only once. P-values represent McNemar’s for matched pair 
differences between baseline and postoperative follow-up. NA-Not applicable. NR – Not recorded. 




 Hereditary Spherocytosis 
(n=110) 
Sickle Cell Disease 
(n=97) 
 Baseline Post-op P-value Baseline Post-op P-value 
Splenic Sequestration NA NA  82 0 <0.001 
Hypersplenism  25 7 <0.001 NA NA  
Transfusions 18 1 <0.001 28 27 1.00 
Aplastic or anemic crisis 11 NR  1 NR  
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TABLE 4 Short-Term and Long-Term Adverse Events (AE) in Children with Hereditary Spherocytosis 
or Sickle Cell Disease Undergoing Total Splenectomy (TS) or Partial Splenectomy (PS).  
Adverse Events Overall Hereditary 
Spherocytosis 
(n=110) 
Sickle Cell Disease 
(n=97) 
  TS PS TS PS 
N 207 59 51 73 24 
Short-Term (<30 days postoperative)  
    Infection 13 1 4 6 2 
    Reoperation 1 1 0 0 0 
    Acute Chest Syndrome 10 NA NA 5 5 
Long-Term (30 days to 5 years)  
Thrombotic Events 5 0 0 5 0 
Sepsis/Bacteremia 6 1 0 5 0 
Meningitis 1 1 0 0 0 
Other infection requiring hospitalization 54 6 7 28 13 
Acute Chest Syndrome 26 NA NA 23 3 
Gallstones 8 0 4 3 1 
Completion Splenectomy  3 NA 3 NA 0 
 
NA – Not applicable. Data are summarized as overall incidence of each adverse event with all 
outcomes based on standard data definitions.
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